Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Boehringer Ingelheim
Related studies linked through entity extraction aliases.
Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study
- Status
- COMPLETED
- Phase
- PHASE3
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
- Status
- COMPLETED
- Phase
- PHASE2
Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients
- Status
- COMPLETED
- Phase
- PHASE3
Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food
- Status
- COMPLETED
- Phase
- PHASE1
Study in Healthy Male Subjects to Investigate Whether Ketoconazole Affects Plasma Exposure of BI 113823
- Status
- COMPLETED
- Phase
- PHASE1
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
- Status
- COMPLETED
- Phase
- PHASE4
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
- Status
- COMPLETED
- Phase
- PHASE3
Telmisartan, Amlodipine and Combination in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Tiotropium Bromide in Cystic Fibrosis
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
- Status
- COMPLETED
- Phase
- PHASE3
Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome
- Status
- COMPLETED
- Phase
- N/A
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
- Status
- COMPLETED
- Phase
- PHASE3
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I
- Status
- COMPLETED
- Phase
- PHASE3
Bioequivalence of a Fixed Dose Combination Tablet Containing 200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl Compared to RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) as a Fixed Dose Combination Tablet Administered in Healthy Volunteers.
- Status
- COMPLETED
- Phase
- PHASE1
Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS
- Status
- COMPLETED
- Phase
- N/A
Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
- Status
- COMPLETED
- Phase
- PHASE2
BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment
- Status
- COMPLETED
- Phase
- PHASE3